Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Conditions:   Mesothelioma;   Non Small Cell Lung Cancer;   Malignant Peripheral Nerve Sheath Tumors;   Solid Tumor;   Pancreatic Adenocarcinoma;   Advanced Solid Tumor
Intervention:   Drug: MRTX1719
Sponsor:   Mirati Therapeutics Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 19, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments